

Current Status of Cancer Immunotherapy in Lebanon, Sudan, and Iraq: A Descriptive and Analytical Cross-Sectional Study of Implementation Barriers and Opportunities

23 ردًا


نشر التحليلات

Section 2: Professional Demographics

نسخ


Country of Practice

23 ردًا




Primary Specialist

ردأ 23



Years of Clinical Experience in Oncology


ردأ 23



Section 3: Clinical Practice & Availability of immunotherapy (e.g., Checkpoint Inhibitors)


Current availability in your clinical setting

ردأ 23




Which immunotherapy agents are most frequently utilized in your practice

ردأ 23




In which line of treatment do you most commonly prescribe immunotherapy

ردأ 23



How often are predictive biomarkers (e.g., PD-L1 expression, MSI/dMMR testing) available before starting treatment


ردأ 23



Section 4: Barriers and Socio-Economic Impact

What is the primary source of funding for patients receiving immunotherapy in your center

ردأ 23



Rank the following barriers from 1 (Lowest) to 5 (Highest) based on their impact on limiting immunotherapy access

ردود 3

Black_ market /governmental coverage/logistic problems/economic crisis/ high cost

5


3

High cost of medications [1-2-3-4-5]

23 ردًا

Average rating (4.17)

-  1
-  2
-  3
-  4
-  5



Lack of specialized diagnostic infrastructure [1-2-3-4-5]

23 ردًا

Average rating (3.57)



1



2




3



4



5



Pharmaceutical supply chain disruptions [1-2-3-4-5]

23 ردًا

Average rating (3.74)



1



2




3



4



5



Lack of specialized professional training [1-2-3-4-5]

23 ردًا

Average rating (2.96)



1



2




3



4



5



Political/Economic instability [1-2-3-4-5]

23 ردًا

Average rating (3.83)



1



2




3



4




5



Do you agree that the current economic/political situation in your country has significantly decreased access to innovative cancer therapies


23 ردًا



Section 5: Clinical Readiness & Knowledge


How would you rate your familiarity with international guidelines (ASCO/ESMO) for managing Immune-Related Adverse Events (irAEs)

23 ردًا



Is your facility equipped with the necessary supportive care (ICU, steroids, consultants) to manage ?severe immunotherapy toxicities


23 ردأ



Section 6: Future Recommendations


What is the most critical intervention needed to improve immunotherapy integration in your country

23 ردأ



Please describe the single biggest challenge you faced when prescribing immunotherapy for your patients

19 ردًا



لم يتم إنشاء هذا المحتوى ولا اعتماده من قبل Google. - مالك نموذج التواصل -
شروط الخدمة - سياسة الخصوصية

هل يبدو هذا النموذج مريباً؟ الإبلاغ

نماذج Google